StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
13
Publishing Date
2022 - 04 - 22
1
2022 - 02 - 28
1
2022 - 02 - 10
1
2021 - 12 - 21
1
2021 - 09 - 24
1
2021 - 09 - 08
1
2021 - 06 - 30
1
2021 - 06 - 14
1
2021 - 05 - 03
1
2021 - 02 - 26
1
2021 - 02 - 22
1
2021 - 01 - 28
1
2020 - 12 - 28
1
Sector
Health technology
13
Tags
Agreement
2
Alliances
3
Antibody
3
Application
4
Approval
10
Approved
4
Australia
4
Authorization
24
Authorized
5
Awards
3
Biocapital
29
Biopharma
3
Bioscience
2
Biotech
2
Biotechnology
22
Canada
3
Candidate
2
Chmp
3
Clinical-trials-phase-ii
3
Clinical-trials-phase-iii
4
Conference
26
Congress
2
Covid
67
Covid-19
93
Deadline
5
Disease
7
Earnings
6
Emergency use authorization
10
Europe
9
Events
9
Fda
11
Financial
10
Financial results
7
Global
3
Grant
5
Granted
8
Grants
3
Health
7
India
10
Influenza
7
License
3
Merge
9
N/a
131
Nuvaxovid
3
Nvx-cov2373
5
Offering
6
People
4
Phase 2
5
Phase 2b
3
Phase 3
13
Positive
6
Product-news
3
Prototype
5
Research
10
Results
27
Submission
5
Switzerland
3
Trial
20
Vaccine
132
World
3
Entities
Abbvie inc.
30
Achieve life sciences, inc.
6
Adial pharmaceuticals, inc
11
Albireo pharma, inc.
6
Aldeyra therapeutics, inc.
11
Alnylam pharmaceuticals, inc.
23
Amgen inc.
7
Apellis pharmaceuticals, inc.
10
Arcutis biotherapeutics, inc.
11
Astrazeneca plc
7
Avadel pharmaceuticals plc
7
Bausch health companies inc.
6
Beigene, ltd.
8
Beyondspring, inc.
10
Biogen inc.
12
Biohaven pharmaceutical holding company ltd.
8
Biomarin pharmaceutical inc.
8
Brickell biotech, inc.
12
Bristol-myers squibb company
12
Cassava sciences, inc.
9
Citius pharmaceuticals, inc.
9
Coherus biosciences, inc.
13
Crinetics pharmaceuticals, inc.
8
Cyclo therapeutics inc - class a
6
Cytokinetics, incorporated
6
Dynavax technologies corporation
11
Eiger biopharmaceuticals, inc.
9
Eli lilly and company
47
Exelixis, inc.
10
Gilead sciences, inc.
9
Humanigen, inc.
9
I-mab
9
Ideaya biosciences, inc.
8
Incyte corporation
23
Inovio pharmaceuticals, inc.
8
Ionis pharmaceuticals, inc.
9
Jazz pharmaceuticals plc
7
Johnson & johnson
29
Madrigal pharmaceuticals, inc.
8
Merck & company, inc.
18
Mesoblast limited
9
Moderna, inc.
10
Myovant sciences ltd.
11
Novan, inc.
10
Novavax, inc.
13
Novocure limited
8
Ocuphire pharma inc.
8
Onconova therapeutics, inc.
7
Oramed pharmaceuticals inc.
7
Pfizer, inc.
21
Regeneron pharmaceuticals, inc.
26
Sanofi
44
Scynexis, inc.
12
Sorrento therapeutics, inc.
8
Takeda pharmaceutical company limited
19
Teva pharmaceutical industries ltd
15
Tg therapeutics, inc.
18
Tonix pharmaceuticals holding corp.
10
Veru inc.
10
Zealand pharma a/s
7
Symbols
NVAX
13
TAK
1
Exchanges
Nasdaq
13
Nyse
1
Crawled Date
2022 - 04 - 22
1
2022 - 02 - 28
1
2022 - 02 - 11
1
2021 - 12 - 21
1
2021 - 09 - 24
1
2021 - 09 - 08
1
2021 - 06 - 30
1
2021 - 06 - 14
1
2021 - 05 - 03
1
2021 - 02 - 26
1
2021 - 02 - 22
1
2021 - 01 - 28
1
2020 - 12 - 28
1
Crawled Time
00:00
1
01:00
1
10:00
1
12:00
1
12:03
1
12:57
1
13:00
1
14:00
1
15:00
1
22:00
1
22:01
1
23:00
2
Source
www.biospace.com
5
www.globenewswire.com
3
www.prnewswire.com
5
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Phase 3
entities :
Novavax, inc.
save search
Novavax Announces Initiation of COVID-19 Vaccine Booster Study in Adolescents in Phase 3 PREVENT-19 Trial
Published:
2022-04-22
(Crawled : 12:00)
- biospace.com/
NVAX
|
$4.19
2.95%
3.21%
3M
|
Health Technology
|
-92.21%
|
O:
-12.19%
H:
4.08%
C:
-1.27%
covid-19
vaccine
trial
phase 3
Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial
Published:
2022-02-28
(Crawled : 23:00)
- biospace.com/
NVAX
|
$4.19
2.95%
3.21%
3M
|
Health Technology
|
-94.87%
|
O:
-0.81%
H:
3.12%
C:
2.96%
covid-19
trial
covid
disease
vaccine
infection
phase 3
infections
Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial
Published:
2022-02-10
(Crawled : 00:00)
- biospace.com/
NVAX
|
$4.19
2.95%
3.21%
3M
|
Health Technology
|
-95.44%
|
O:
-4.98%
H:
0.0%
C:
0.0%
covid-19
trial
covid
event-19
positive results
positive
vaccine
phase 3
Novavax Announces Initiation of PREVENT-19 COVID-19 Vaccine Phase 3 Trial Booster Study
Published:
2021-12-21
(Crawled : 23:00)
- prnewswire.com
NVAX
|
$4.19
2.95%
3.21%
3M
|
Health Technology
|
-97.81%
|
O:
0.11%
H:
1.0%
C:
-4.17%
event-19
covid-19
trial
covid
vaccine
phase 3
Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases
Published:
2021-09-24
(Crawled : 01:00)
- prnewswire.com
NVAX
|
$4.19
2.95%
3.21%
3M
|
Health Technology
|
-98.37%
|
O:
0.0%
H:
0.0%
C:
0.0%
disease
infectious disease
results
vaccine
influenza
phase 3
trial
lancet
Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza
Published:
2021-09-08
(Crawled : 13:00)
- biospace.com/
NVAX
|
$4.19
2.95%
3.21%
3M
|
Health Technology
|
-98.45%
|
O:
0.92%
H:
1.74%
C:
-2.29%
covid
phase 1
vaccine
influenza
trial
phase 2
phase 3
covid-19
Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine
Published:
2021-06-30
(Crawled : 22:00)
- prnewswire.com
NVAX
|
$4.19
2.95%
3.21%
3M
|
Health Technology
|
-98.03%
|
O:
1.27%
H:
0.47%
C:
0.35%
covid
results
vaccine
phase 3
trial
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
Published:
2021-06-14
(Crawled : 10:00)
- prnewswire.com
NVAX
|
$4.19
2.95%
3.21%
3M
|
Health Technology
|
-98.0%
|
O:
7.52%
H:
1.8%
C:
-7.86%
covid
disease
vaccine
phase 3
trial
Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine
Published:
2021-05-03
(Crawled : 12:57)
- prnewswire.com
NVAX
|
$4.19
2.95%
3.21%
3M
|
Health Technology
|
-98.23%
|
O:
0.66%
H:
0.54%
C:
-18.19%
covid
expansion
vaccine
phase 3
trial
covid-19
Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
Published:
2021-02-26
(Crawled : 14:00)
- biospace.com/
TAK
|
News
|
$13.38
0.15%
1.94%
1.7M
|
Health Technology
|
-20.33%
|
O:
0.72%
H:
0.5%
C:
-0.95%
NVAX
|
$4.19
2.95%
3.21%
3M
|
Health Technology
|
-98.11%
|
O:
1.81%
H:
3.52%
C:
2.54%
covid
phase 1
vaccine
license
trial
phase 3
phase 2
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
Published:
2021-02-22
(Crawled : 12:03)
- globenewswire.com
NVAX
|
$4.19
2.95%
3.21%
3M
|
Health Technology
|
-98.49%
|
O:
-3.56%
H:
3.41%
C:
-8.55%
covid
vaccine
phase 3
trial
enroll
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
Published:
2021-01-28
(Crawled : 22:01)
- globenewswire.com
NVAX
|
$4.19
2.95%
3.21%
3M
|
Health Technology
|
-96.87%
|
O:
42.56%
H:
23.27%
C:
15.65%
covid
vaccine
phase 3
trial
covid-19
Novavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico
Published:
2020-12-28
(Crawled : 15:00)
- globenewswire.com
NVAX
|
$4.19
2.95%
3.21%
3M
|
Health Technology
|
-96.76%
|
O:
-0.07%
H:
0.58%
C:
-9.59%
covid
vaccine
phase 3
trial
Gainers vs Losers
78%
22%
Top 10 Gainers
MTTR
|
News
4
|
$4.6
164.37%
62.17%
26M
|
AGBA
|
$2.97
137.6%
57.48%
66M
|
Finance
EDBL
|
News
|
$6.59
75.27%
41.8%
2M
|
ZAPP
|
$4.44
50.2%
33.12%
370K
|
n/a
MTC
|
$2.24
43.59%
30.67%
6M
|
Technology Services
OPRT
|
News
|
$3.15
40.0%
29.13%
12M
|
Finance
SHIM
|
$3.045
35.33%
26.23%
870K
|
HKIT
|
$1.33
30.39%
24.16%
390K
|
Technology Services
ABVC
|
$1.35
29.81%
23.53%
7.1M
|
Wholesale Trade
OST
|
$0.5
25.0%
21.88%
280K
|
Your saved searches
Save your searches and get alerts when important news are released.